Canton Biotechnologies Overview
- Founded
-
2004

- Status
-
Private
- Employees
-
2

- Latest Deal Type
-
2ndary - Private
- Investors
-
4
Canton Biotechnologies General Information
Description
Developer of innovative wound healing technology designed to provide high-value therapeutics. The company's technology uses CA5 HIF plasmid transfection with electroporation, enabling patients and health institutions to avail fast and effective cure to accelerate wound healing in acute and chronic wounds.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Outcome Management (Healthcare)
Discovery Tools (Healthcare)
Primary Office
- 2601 Boston Street
- Suite 606
- Baltimore, MD 21224
- United States
+1 (410) 000-0000
Canton Biotechnologies Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Secondary Transaction - Private | 01-Feb-2021 | 0000 | Completed | Generating Revenue | ||
3. Grant | 01-Jan-2015 | 00000 | 0000 | Completed | Generating Revenue | |
2. Early Stage VC | 17-Aug-2006 | $80K | $80K | Completed | Startup | |
1. Accelerator/Incubator | Completed | Startup |
Canton Biotechnologies Executive Team (2)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
John Harmon MD | President |
Canton Biotechnologies Signals
Canton Biotechnologies Investors (4)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
National Institutes of Health | Government | 000 0000 | 000000 0 | ||
United States Department of Defense | Government | 000 0000 | 000000 0 | ||
U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 | ||
Johns Hopkins Technology Ventures | Accelerator/Incubator | 000 0000 | 000000 0 |